#ibrexafungerp

SCYNEXIS and Hansoh Pharma announce licensing agreement and strategic partnership for Ibrexafungerp in Greater China

Partnership aims to accelerate access to breakthrough therapies in order to combat difficult-to-treat and often drug-resistant fungal infections in Greater China SCYNEXIS will receive a $10 million upfront payment and will also be eligible to receive development and commercial milestones, plus low double-digit royalties on net product sales Ibrexafungerp is a first-in-class, broad-spectrum…